Thomas highlights the Mesa study, revealing a significant reduction in cardiovascular risk with aspirin use for individuals with LP above 50 mg/dL. He delves into the anti-inflammatory properties of aspirin and the potential benefits for those with elevated LP levels due to its binding with oxidized phospholipids, a major driver of inflammation in atherosclerotic disease.
